Metformin in non-alcoholic steatohepatitis
- PMID: 11567710
- DOI: 10.1016/s0140-6736(01)06042-1
Metformin in non-alcoholic steatohepatitis
Abstract
There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steatohepatitis but were not alcoholics with metformin (500 mg three times a day for 4 months), an agent that improves hepatic insulin sensitivity. When compared with the six individuals not complying with treatment, long-term metformin significantly reduced mean transaminase concentrations, which returned to normal in 50% of actively-treated patients. Also, insulin sensitivity improved significantly and liver volume decreased by 20%. Similar data have been reported in insulin-resistant ob/ob mice with fatty liver. A randomised-controlled study is needed.
Comment in
-
Metformin in non-alcoholic steatohepatitis.Lancet. 2002 Jan 26;359(9303):355-6. doi: 10.1016/S0140-6736(02)07566-9. Lancet. 2002. PMID: 11830232 No abstract available.
Similar articles
-
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.Am J Gastroenterol. 2005 May;100(5):1082-90. doi: 10.1111/j.1572-0241.2005.41583.x. Am J Gastroenterol. 2005. PMID: 15842582 Clinical Trial.
-
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.Am J Gastroenterol. 2006 Jun;101(6):1396; author reply 1396-7. doi: 10.1111/j.1572-0241.2006.00595_1.x. Am J Gastroenterol. 2006. PMID: 16771968 No abstract available.
-
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.Aliment Pharmacol Ther. 2008 Jul;28(2):200-8. doi: 10.1111/j.1365-2036.2008.03723.x. Epub 2008 Apr 25. Aliment Pharmacol Ther. 2008. PMID: 18445142 Clinical Trial.
-
Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.Am J Gastroenterol. 2003 Sep;98(9):2093-7. doi: 10.1111/j.1572-0241.2003.07670.x. Am J Gastroenterol. 2003. PMID: 14499793 Review.
-
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. doi: 10.1002/14651858.CD005166.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253544 Review.
Cited by
-
Pharmacological agents for nonalcoholic steatohepatitis.Hepatol Int. 2013 Dec;7 Suppl 2:833-41. doi: 10.1007/s12072-013-9482-8. Epub 2013 Nov 19. Hepatol Int. 2013. PMID: 26202298
-
Revision and update on clinical practice guideline for liver cirrhosis.Korean J Hepatol. 2012 Mar;18(1):1-21. doi: 10.3350/kjhep.2012.18.1.1. Epub 2012 Mar 22. Korean J Hepatol. 2012. PMID: 22511898 Free PMC article. No abstract available.
-
Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation.Dig Dis Sci. 2006 Jul;51(7):1226-9. doi: 10.1007/s10620-006-8038-3. Dig Dis Sci. 2006. PMID: 16944015 No abstract available.
-
Fatty liver disease in children.Arch Dis Child. 2004 Jul;89(7):648-52. doi: 10.1136/adc.2003.029942. Arch Dis Child. 2004. PMID: 15210498 Free PMC article. Review.
-
Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.World J Gastroenterol. 2014 Jan 14;20(2):569-77. doi: 10.3748/wjg.v20.i2.569. World J Gastroenterol. 2014. PMID: 24574727 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
